Table 1. Summary of mpox research studies and programmes taking place as of December 2023.

Study type	Study title	Sponsor	Location	Clade primarily studied	Target sample size	Status	Trial registration ID
RCT	PLATINUM-UK	University of Oxford	United Kingdom	Clade IIb	450	Stopped recruiting	ISRCTN17461766
RCT	PLATINUM-CAN	McGill University	Canada	Clade IIb	120	Not yet recruiting	NCT05534165
RCT	STOMP	NIAID/DAIDS	Multiple countries	Clade IIb	530	Actively recruiting	NCT05534984
RCT	UNITY	Hospital University Geneva (HUG)	Brazil, Argentina, Switzerland	Clade IIb	150	Actively recruiting	NCT05597735
RCT	EPOXI	UMC Utrecht ECRAID	Multiple countries (Europe)	Clade IIb	644	In set-up	NK
RCT	MOSA	PANTHER	Multiple countries (Africa)	Clade I and IIa	500	In set-up	NK
RCT	PALM007	NIAID	Democratic Republic of Congo	Clade I	450	Actively recruiting	NCT05559099
EAP	-	US Army Medical Research and Development Command	United States	Clade IIa	NA	Actively recruiting	NCT02080767
EAP	Tecovirimat for mpox in CAR	University of Oxford	Central African Republic	Clade I	NA	Actively recruiting	ISRCTN43307947
MEURI	-	WHO	Global	All clades	NA	Actively recruiting	NA
Observational/LICT	MOSAIC	University of Oxford	Multiple countries (Europe)	Clade IIb	NA	Stopped recruiting	2022-501132-42-00
Observational	UK CCP	University of Oxford	United Kingdom	All clades	NA	Actively recruiting (stopped recruiting clade IIb)	NA
Observational	NETPOX	Hospital Israelita Albert Einstein	Brazil	Clade IIb	80	In set-up	NCT05784038

CAR, Central African Republic; CTIS, Clinical Trials Information System; EAP, Expanded Use Protocol; EMA, European Medicine Agency; EU, European Union; LICT, Low Interventional Clinical Trial; PHEIC, Public Health Emergency of International Concern; UK, United Kingdom; US, United States.